Buspirone in ADHD
Abstract
Buspirone monotherapy (0.5 mg/kg daily for 6 weeks) was evaluated in 12 children (10 boys, 2 girls), aged 6 to 12 years, with ADHD at the Maudsley Hospital, London, UK.
DOI: https://doi.org/10.15844/pedneurbriefs-12-4-12 | Journal eISSN: 2166-6482
Language: English
Page range: 32 - 32
Published on: Apr 1, 1998
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services
Keywords:
© 1998 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.